AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress

Mount Carmel Register

Sep 30, 2021

AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress |!| Mount Carmel